Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the
appointment of Erica Jordan, Senior Vice President of Commercial to
Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have
global responsibility for all aesthetics commercial activity
including commercial strategy, sales and marketing, branding,
loyalty and engagement.
“Given the importance of the DAXXIFY® launch, I’m excited to
elevate Erica to the position of Chief Commercial Officer,
Aesthetics reporting directly to me. Having worked closely with
Erica over the past several months, I have tremendous confidence in
her abilities and leadership skills, and she’s been an invaluable
partner as we’ve evolved our strategy based on customer feedback.
In this role, Erica will not only help us drive the desired DAXXIFY
adoption but also help ensure that we continue to grow our RHA®
filler business and begin to realize the synergies of our
portfolio,” said Mark J. Foley, Chief Executive Officer of Revance.
“Erica joined us earlier this year and has a demonstrated track
record as a global healthcare leader driving commercial
transformation and growth, sales and marketing excellence, flagship
product launches and operational efficiencies. Her extensive
experience and strong ability to build partnerships both internally
and externally, will be invaluable as we seek to maximize the
market opportunity of our innovative products.”
“I’ve seen first-hand the tremendous excitement and potential
that our product portfolio offers to the aesthetics market,” said
Erica Jordan, Chief Commercial Officer, Aesthetics of Revance.
“With key launch initiatives underway, I look forward to working
with Mark and the rest of the team to continue to elevate Revance
and its portfolio of products in the aesthetics marketplace. We
will build on our progress, leverage learnings and partner with our
current customers to continue to establish the value of
DAXXIFY.”
Ms. Jordan joined Revance earlier this year as Senior Vice
President of Commercial, bringing 25 years of marketing, sales
management, commercial strategy, commercial operations and
management experience at leading global healthcare companies. Prior
to joining Revance, she served as President of the Metrex division
at Envista Holdings, where she developed and executed a successful
commercial strategy and implemented operational efficiencies to
support double-digital growth. There, she also held the role of
Senior Vice President, Sales & Marketing for the Ormco division
where she successfully launched multiple new products and enabled
significant market share growth for the flagship product
categories. Before Envista Holdings, Ms. Jordan served as Vice
President, Global Marketing for Change Healthcare where she
developed and executed the commercial strategy for the first-ever
cloud-based radiology enterprise imaging platform. She has held
several marketing, commercial and operational leadership roles at
Phillips Healthcare, including her role as Vice President, Senior
General Manager, where she built the commercial team and the
go-to-market strategy for the newly acquired women’s healthcare
business. In addition, she held senior leadership roles at Fujifilm
Medical Systems, Siemens Medical Solutions and GE Healthcare.
Ms. Jordan received her B.S. in Marketing and Finance from the
University of Wisconsin-Milwaukee and is an active member of the
Women Business Leaders of the US Health Care Industry
Foundation.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for
injection and the RHA® Collection of dermal fillers in the U.S.
Revance has also partnered with Viatris Inc. to develop a
biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun
Pharmaceutical to commercialize DAXXIFY® in China.
Revance is headquartered in Nashville, Tenn., with additional
office locations in Newark and Irvine, Calif. Learn more at
www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com,
www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.
“Revance”, the Revance logo, and DAXXIFY® are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
Forward-Looking Statements
Any statements in this press release that are not statements of
historical fact, including statements related to our potential to
drive DAXXIFY adoption; our market opportunity; the growth
potential of the RHA Collection of dermal fillers; our ability to
realize the synergies of our portfolio of products; our ability to
establish the value of DAXXIFY; the potential to set a new standard
of care; the potential benefits of our products; the extent to
which our products are considered innovative; the commercialization
of DAXXIFY through our Fosun partnership; development of a
biosimilar to onabotulinumtoxinA for injection with our partner,
Viatris; and our business and marketing strategy, timeline, goals,
plans and prospects; constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. You
should not rely upon forward-looking statements as predictions of
future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot
guarantee that the future results, levels of activity, performance,
events, circumstances or achievements reflected in the
forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties relate to, but
are not limited to: our ability to obtain funding for our
operations; the timing of capital expenditures; the accuracy of our
estimates regarding expenses, revenues, capital requirements, our
financial performance and the economics of DAXXIFY and the RHA
Collection of dermal fillers; the extent of future impairment
charges; our ability to comply with our debt obligations; the
impact of macroeconomic factors on our manufacturing operations,
supply chain, end user demand for our products, commercialization
efforts, business operations, regulatory meetings, inspections and
approvals, clinical trials and other aspects of our business and on
the market; our ability to maintain approval of our products; our
ability and the ability of our partners to manufacture supplies for
DAXXIFY and our drug product candidates; our ability to acquire
supplies of the RHA Collection of dermal fillers; the uncertain
clinical development process; our ability to obtain, and the timing
relating to, regulatory submissions and approvals with respect to
our drug product candidates and third-party manufacturers; the risk
that clinical trials may not have an effective design or generate
positive results or that positive results would assure regulatory
approval or commercial success; the applicability of clinical study
results to actual outcomes; the rate and degree of economic
benefit, safety, efficacy, commercial acceptance, market,
competition and/or size and growth potential of DAXXIFY, the RHA
Collection of dermal fillers, and our drug product candidates, if
approved; our ability to successfully commercialize DAXXIFY and to
continue to successfully commercialize the RHA Collection of dermal
fillers; the timing and cost of commercialization activities;
securing or maintaining adequate coverage or reimbursement by
third-party payers for DAXXIFY; the proper training and
administration of our products by physicians and medical staff; our
ability to maintain and gain acceptance from injectors in the use
of DAXXIFY for aesthetic and therapeutic indications; our ability
to expand sales and marketing capabilities; the status of
commercial collaborations; our ability to effectively manage the
exit of the OPUL payments business; changes in and failures to
comply with laws and regulations; our ability to continue obtaining
and maintaining intellectual property protection for our products;
the cost and our ability to defend ourselves in product liability,
intellectual property, class action or other lawsuits; our ability
to limit or mitigate cybersecurity incidents; the volatility of our
stock price; and other risks. Detailed information regarding
factors that may cause actual results to differ materially from the
results expressed or implied by statements in this press release
may be found in our periodic filings with the Securities and
Exchange Commission (SEC), including factors described in the
section entitled "Risk Factors" in our Form 10-K filed with the SEC
on February 28, 2023, and including, without limitation, our Form
10-Qs for the quarters ended March 31, 2023 and June 30, 2023,
filed on May 9, 2023 and August 8, 2023, respectively, and our Form
10-Q for the quarter ended September 30, 2023 expected to be filed
November 8, 2023. The forward-looking statements in this press
release speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108697331/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara J. Fahy,
949-887-4476 sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Revance Therapeutics (NASDAQ:RVNC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024